Trial Profile
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoptarelin doxorubicin (Primary) ; Capecitabine; Doxorubicin liposomal; Eribulin; Gemcitabine; Paclitaxel; Vinorelbine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 14 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 04 Jun 2013 Study design presented at 49th Annual Meeting of the American Society of Clinical Oncology (ASCO 2013).
- 01 Jun 2013 Information from this trial will be presented as a poster at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013).